Navigation Links
Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
Date:6/30/2008

- Phase II Trial Shows Increase in Mature Dendritic Cells -

WAYNE, N.J., June 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals today confirmed that results of a Phase II trial were published in the July 1 edition of the Journal of Clinical Oncology. The study showed that Leukine(R) (sargramostim) demonstrated a median overall survival of 65 months and increased mature dendritic cells in high-risk melanoma patients. Dendritic cells are special antigen-presenting cells that help the immune system recognize cancer cells and are the most effective antigen-presenting cells known. Study authors concluded that this increase in dendritic cell counts may also correlate with delayed recurrence of disease.

"These data provide early signals that Leukine may offer clinical benefit in this patient group by increasing and differentiating dendritic cells and perhaps by benefiting patients who have lowered baseline levels of dendritic cells," said Dr. Adil Daud, first author of the study and Associate Professor, Director, Clinical Research, University of California, San Francisco Melanoma Center. "Patients who experienced an increase of dendritic cells were more likely to demonstrate delayed disease recurrence."

In this Phase II prospective trial, 42 patients with resected high-risk (Stage IIIB, IIIC or IV) melanoma were treated with Leukine (125 mcg/m2/day for 14 consecutive days followed by 14 days of no treatment). This regimen was repeated for 13 cycles unless patients had unacceptable toxicity or showed evidence of disease recurrence. Patients had no evidence of disease at the start of the trial as measured by imaging. Patients underwent restaging every four months. The most common adverse events found in the study were injection site reactions (88 percent), pain (61 percent), arthralgia/myalgia (61 percent), fatigue (61 percent), flu-like symptoms (39 percent) and insomnia (27 percent).

Of the 42 enrolled patients, 39 were av
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
2. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
3. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
4. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
5. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
6. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
7. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
10. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
11. Multi Merci Trial Results Published in Peer Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... DIEGO , July 22, 2014  Halozyme Therapeutics, ... it has resumed enrollment and dosing of patients in ... in patients with pancreatic cancer under the revised clinical ... is an investigational PEGylated form of Halozyme,s proprietary recombinant ... tumors that accumulate hyaluronan. "Our diligent ...
(Date:7/22/2014)... YORK , July 22, 2014 /PRNewswire-iReach/ -- ... New York ), a nationally and ... for patients requiring reproductive assistance, is pleased to announce ... Corps and Compassionate Care Programs to recognize the sacrifices ... The Compassionate Corps Program will allow qualifying ...
(Date:7/22/2014)... , July 22, 2014 The steady ... is spreading to previously rep-friendly specialties, according to ... and marketing consulting firm ZS Associates.      ... 200 U.S. pharmaceutical sales teams. The report examines ... meet with the pharmaceutical sales reps who visit ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5
... ("Senesco" or the "Company") (NYSE Amex: SNT ) ... conducted in Dr. William Scheld,s lab at the University of ... against Senesco,s Factor 5A gene had a 52% survival rate as ... treatment or a control siRNA.A total of 73 mice were infected ...
... announced today that eleven presentations or publications on pre-clinical ... in several major tumor types will be made during ... Meeting, May 29-June 2, in Orlando, Florida. Abstracts ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate ...
Cached Medicine Technology:Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... Legislation backed by the drugstore lobby ... Act of 2014”) championing so-called “any willing pharmacy” ... availability of lower cost preferred pharmacy networks and ... next 10 years, according to new research from ... Management Association (PCMA). , The drugstore lobby targets ...
(Date:7/22/2014)... -- New guidelines on cholesterol treatment and cardiovascular risk ... risk of dying from atherosclerotic cardiovascular disease or of ... with a similar risk profile (based on age, smoking ... of this finding for when and how aggressively to ... Journal of Men,s Health , a peer-reviewed publication ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... (HealthDay News) -- One of the largest studies ever ... has uncovered 83 new sites on chromosomes that harbor ... by an international team of researchers, now bring the ... disorder to 108. Although these schizophrenia-associated genes ... to predict who will or will not develop the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... brain cells suddenly went rogue and decided to become fat ... early in an organism,s development, cells make firm and more-or-less ... say, skin cells, brain cells or, well, fat cells. ... the possible candidates encoded in a cell,s genes, the cell ...
... SUNDAY, March 20 (HealthDay News) -- People with asthma may ... according to a new study that looked at the relationship ... which looked at medical records from the late 1960s through ... illness among asthmatics than other people. Researchers led by ...
... ill in Britain, according to new research published today by ... of almost 800 patients with severe mental illness such as ... or obese, and a disproportionate number suffered from diabetes, heart ... results of the two-year project in Kent are published today ...
... HealthDay Reporter , SATURDAY, March 19 (HealthDay News) -- ... quickly as experts previously have believed. In a study ... third outgrew it within 30 months. But that finding ... higher percentage of children outgrowing the allergy fairly quickly, said ...
... Today, during the 89th General Session & Exhibition of ... with the 40th Annual Meeting of the American Association ... the Canadian Association for Dental Research, lead researcher F. ... study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans ...
... 18, 2011)--The growing concern surrounding the release of ... in Japan has raised fears of radiation exposure ... plume of radioactivity crossing the Pacific Ocean. To ... American Association of Clinical Endocrinologists (AACE), the American ...
Cached Medicine News:Health News:Stanford researchers discover molecular determinant of cell identity 2Health News:Stanford researchers discover molecular determinant of cell identity 3Health News:Stanford researchers discover molecular determinant of cell identity 4Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4Health News:Life expectancy of severely mentally ill dramatically reduced due to poor physical health 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 3Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:Radiation risks to health: A joint statement from leading scientific experts 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: